The effectiveness of repurposed medications for treating COVID-19 remains a critical area of investigation. A new analysis found that higher-dose fluvoxamine (Luvox), an antidepressant with ...
In a recent study published in the Annals of Internal Medicine, researchers performed a randomized, placebo-controlled trial (RCT) among adults with confirmed severe acute respiratory syndrome ...
In a recent study published in the Journal of American Medical Association, researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate coronavirus disease 2019 ...
The extensive quest to repurpose a cheap therapy for non-hospitalized COVID patients has once again fallen short, this time using a higher dose of fluvoxamine (Luvox), a selective serotonin reuptake ...
About The Study: Among outpatient adults with mild to moderate COVID-19, treatment with fluvoxamine 100 mg twice daily for 13 days, compared with placebo, did not improve time to sustained recovery in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback